CNBC reports Takeda is considering submitting a bid for British drugmaker Shire, to expand its U.S. presence.
Here's what you should know.
1. Shire creates pharmaceutical treatments for rare diseases and hyperactivity.
2. The rumors sent Shire's stock price rocketing. The drug maker's stock rose 25 percent March 27.
3. Shire is valued at $46.3 billion (£32.7 billion).
4. Takeda confirmed to CNBC its approach was at a preliminary and exploratory stage. Takeda will have until April 25 to make a bid.